Antigrowth factor strategies

Cancer. 1993 Feb 1;71(3 Suppl):1172-8. doi: 10.1002/1097-0142(19930201)71:3+<1172::aid-cncr2820711441>3.0.co;2-z.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II

MeSH terms

  • Apoptosis / physiology
  • Cell Division / physiology
  • Extracellular Matrix / physiology
  • Growth Inhibitors / therapeutic use*
  • Growth Substances / physiology
  • Humans
  • Male
  • Neoplasm Staging
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / therapy*
  • Receptors, Purinergic / physiology
  • Signal Transduction / physiology
  • Suramin / metabolism
  • Suramin / pharmacology
  • Suramin / therapeutic use*

Substances

  • Growth Inhibitors
  • Growth Substances
  • Receptors, Purinergic
  • Suramin
  • Prostate-Specific Antigen